Literature DB >> 15104276

The role of the THY1 gene in human ovarian cancer suppression based on transfection studies.

Harindra R Abeysinghe1, Stephen J Pollock, Nedra L Guckert, Yana Veyberman, Peter Keng, Marc Halterman, Howard J Federoff, Joseph P Rosenblatt, Nancy Wang.   

Abstract

In our recent studies, the expression of the THY1 gene encoding a 25-28 kDa glycoprotein located at 11q23-q24, was found to be associated with complete tumor suppression of the ovarian cancer cell line SKOV-3 after the transfer of chromosome 11. These studies raised the possibility that THY1 maybe a candidate tumor suppressor gene for ovarian cancer. To investigate this, the complete cDNA sequence for THY1 was cloned and transfected into SKOV-3 ovarian cancer cells. The expression of THY1 in the transfectants was confirmed by Northern blot analysis, immunocytochemistry, and flow cytometry. Both SKOV-3-THY1 and SKOV-3-null cells were inoculated subcutaneously into severe combined immunodeficiency (SCID) mice to determine in vivo tumorigenicity. THY1 transfectants formed tumors, but overall tumor growth rate and tumor size was significantly reduced compared with their null counterparts. To further correlate THY1 expression with tumorigenicity, the THY1 antisense was transfected into the nontumorigenic clone, 11(C)9-8, which resulted in restoration of tumorigenicity. These data indicate that THY1 expression alone cannot suppress tumorigenicity; however, abrogation of THY1 expression from nontumorigenic cells can restore tumorigenesis. Taken together, the data suggest that THY1 is necessary but not sufficient to suppress ovarian tumorigenicity. Therefore, THY1 can be designated as a putative tumor suppressor gene for human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104276     DOI: 10.1016/S0165-4608(03)00234-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  15 in total

Review 1.  The manipulation of chromosomes by mankind: the uses of microcell-mediated chromosome transfer.

Authors:  Karen J Meaburn; Christopher N Parris; Joanna M Bridger
Journal:  Chromosoma       Date:  2005-10-15       Impact factor: 4.316

Review 2.  Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.

Authors:  Tanya A Rege; James S Hagood
Journal:  Biochim Biophys Acta       Date:  2006-08-18

3.  Methylation profiling of serum DNA from hepatocellular carcinoma patients using an Infinium Human Methylation 450 BeadChip.

Authors:  Pengjun Zhang; Xinyu Wen; Feng Gu; Xinxin Deng; Juan Li; Jin Dong; Jiao Jiao; Yaping Tian
Journal:  Hepatol Int       Date:  2013-09-03       Impact factor: 6.047

4.  Differential profiling studies of N-linked glycoproteins in glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor.

Authors:  Lan Dai; Yashu Liu; Jintang He; Callie G Flack; Caroline E Talsma; Jessica G Crowley; Karin M Muraszko; Xing Fan; David M Lubman
Journal:  Proteomics       Date:  2011-09-08       Impact factor: 3.984

5.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

Review 6.  Multiple roles of CD90 in cancer.

Authors:  Atul Kumar; Anshuman Bhanja; Jina Bhattacharyya; Bithiah Grace Jaganathan
Journal:  Tumour Biol       Date:  2016-06-23

7.  Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin.

Authors:  Wei-Ching Chen; Hui-Ping Hsu; Chung-Yen Li; Ya-Ju Yang; Yu-Hsuan Hung; Chien-Yu Cho; Chih-Yang Wang; Tzu-Yang Weng; Ming-Derg Lai
Journal:  Int J Oncol       Date:  2016-09-15       Impact factor: 5.650

8.  Bleomycin-Treated Chimeric Thy1-Deficient Mice with Thy1-Deficient Myofibroblasts and Thy-Positive Lymphocytes Resolve Inflammation without Affecting the Fibrotic Response.

Authors:  Pazit Y Cohen; Raphael Breuer; Philip Zisman; Shulamit B Wallach-Dayan
Journal:  Mediators Inflamm       Date:  2015-08-02       Impact factor: 4.711

9.  The landscape of candidate driver genes differs between male and female breast cancer.

Authors:  Ida Johansson; Markus Ringnér; Ingrid Hedenfalk
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

10.  A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells.

Authors:  Daniela A Moraes; Tatiana T Sibov; Lorena F Pavon; Paula Q Alvim; Raphael S Bonadio; Jaqueline R Da Silva; Aline Pic-Taylor; Orlando A Toledo; Luciana C Marti; Ricardo B Azevedo; Daniela M Oliveira
Journal:  Stem Cell Res Ther       Date:  2016-07-28       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.